Dear applicants!
The Pharmacovigilance Risk Assessment Committee of the European Medicines Agency (PRAC EMA), having considered the available evidence from reviews submitted by registration certificate holders regarding the risk of lichenoid reaction with the use of medicinal products containing Etanercept, Golimumab, Infliximab. PRAC agreed that registration certificate holders of medicinal products containing Etanercept, Golimumab, Infliximab must, within 2 months (from the date, see the link), amend the section “Adverse reactions” of the instructions for medical use, adding information on the risk of lichenoid reaction.
List of medicinal products containing Etanercept, Golimumab, Infliximab and approved for medical use in Ukraine (according to the State Register of Medicinal Products as of 12.02.2019.
Link:
https://www.ema.europa.eu/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-26-29-november-2018_en.pdf
https://www.ema.europa.eu/documents/prac-recommendation/prac-recommendations-signals-adopted-26-29-november-2018-prac-meeting_en.pdf